pembrolizumab

Survival data
Survival status and ctDNA levels for patients receiving pembrolizumab

datasets

Streamlined statistical reporting in 'Rmarkdown' environments.
Facilitates the automated reporting of descriptive statistics, multiple
univariate models, multivariable models and tables combining these outputs.
Plotting functions include customisable survival curves, forest plots from
logistic and ordinal regression and bivariate comparison plots.

Lisa Avery

reportRmd

Tidy Presentation of Clinical Reporting

Ryan Del Bel

Osvaldo Espin-Garcia

Katherine Lajkosz

Tyler Pittman

Anna Santiago

Yanning Wang

Jessica Weiss

Wei Xu

pembrolizumab function

A data frame with 94 rows and 15 variables:<dl>
<dt>id</dt>
<dd>Patient ID</dd><dt>age</dt>
<dd>Age at study entry</dd><dt>sex</dt>
<dd>Patient Sex</dd><dt>cohort</dt>
<dd>Study Cohort: A = Squamous cell carcinoma of soft pallate, B = Triple negative breast cancer, C = Ovarian, high grade serous, D = Melanoma, E = Other Solid Tumor</dd><dt>l_size</dt>
<dd>Target lesion size at baseline</dd><dt>pdl1</dt>
<dd>PD L1 percent</dd><dt>tmb</dt>
<dd>log of TMB</dd><dt>baseline_ctdna</dt>
<dd>Baseline ctDNA</dd><dt>change_ctdna_group</dt>
<dd>Did ctDNA increase or decrease from baseline to cycle 3</dd><dt>orr</dt>
<dd>Objective Response</dd><dt>cbr</dt>
<dd>Clinical Beneficial Response</dd><dt>os_status</dt>
<dd>Overall survival status, 0 = alive, 1 = deceased</dd><dt>os_time</dt>
<dd>Overall survival time in months</dd><dt>pfs_status</dt>
<dd>Progression free survival status, 0 = progression free, 1 = progressed</dd><dt>pfs_time</dt>
<dd>Progression free survival time in months</dd>
</dl>

Format

Survival data

Survival status and ctDNA levels for patients receiving pembrolizumab — pembrolizumab

A data frame with 94 rows and 15 variables:<dl>
<dt>id</dt>
<dd>Patient ID</dd>

<dt>age</dt>
<dd>Age at study entry</dd>

<dt>sex</dt>
<dd>Patient Sex</dd>

<dt>cohort</dt>
<dd>Study Cohort: A = Squamous cell carcinoma of soft pallate, B = Triple negative breast cancer, C = Ovarian, high grade serous, D = Melanoma, E = Other Solid Tumor</dd>

<dt>l_size</dt>
<dd>Target lesion size at baseline</dd>

<dt>pdl1</dt>
<dd>PD L1 percent</dd>

<dt>tmb</dt>
<dd>log of TMB</dd>

<dt>baseline_ctdna</dt>
<dd>Baseline ctDNA</dd>

<dt>change_ctdna_group</dt>
<dd>Did ctDNA increase or decrease from baseline to cycle 3</dd>

<dt>orr</dt>
<dd>Objective Response</dd>

<dt>cbr</dt>
<dd>Clinical Beneficial Response</dd>

<dt>os_status</dt>
<dd>Overall survival status, 0 = alive, 1 = deceased</dd>

<dt>os_time</dt>
<dd>Overall survival time in months</dd>

<dt>pfs_status</dt>
<dd>Progression free survival status, 0 = progression free, 1 = progressed</dd>

<dt>pfs_time</dt>
<dd>Progression free survival time in months</dd>


</dl>

Survival data

Survival status and ctDNA levels for patients receiving pembrolizumab

Survival dataSurvival status and ctDNA levels for patients receiving pembrolizumab

pembrolizumab: Survival data
Survival status and ctDNA levels for patients receiving pembrolizumab

Description

Usage

Arguments

Format